| Medical and Health Sciences | 2021-2025 | 486 | AU 19 | 99.90 |
| Geriatrics and Gerontology | Lifetime | 113 | AU 8 | 97.24 |
| Cardiology and Cardiovascular Medicine | Lifetime | 916 | AU 27 | 97.85 |
| Rheumatology | Lifetime | 710 | AU 22 | 96.41 |
| Oncology | 2021-2025 | 274 | AU 12 | 97.59 |
| Rheumatology | 2021-2025 | 139 | AU 5 | 96.93 |
| Infectious Diseases | 2021-2025 | 219 | AU 5 | 96.31 |
| Epidemiology | 2021-2025 | 610 | AU 27 | 94.37 |
| Medical Physiology | 2021-2025 | 419 | AU 18 | 94.09 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 493 | AU 21 | 94.60 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 565 | AU 21 | 91.29 |
| Pathology and Forensic Medicine | 2021-2025 | 326 | AU 11 | 89.00 |
| Geriatrics and Gerontology | 2021-2025 | 128 | AU 8 | 86.21 |
| Nephrology | 2021-2025 | 315 | AU 24 | 74.14 |
| Immunology | 2021-2025 | 955 | AU 18 | 59.60 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 35 | AU 2 | 98.57 |
| COVID-19 Clinical Research Studies | Lifetime | 282 | AU 6 | 98.74 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 139 | AU 18 | 98.43 |
| COVID-19 and healthcare impacts | Lifetime | 186 | AU 7 | 96.97 |
| Long-Term Effects of COVID-19 | Lifetime | 405 | AU 7 | 96.86 |
| Cardiovascular Health and Disease Prevention | Lifetime | 713 | AU 33 | 96.98 |
| Folate and B Vitamins Research | Lifetime | 741 | AU 28 | 95.36 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 919 | AU 25 | 96.66 |
| Systemic Sclerosis and Related Diseases | Lifetime | 773 | AU 16 | 95.11 |
| Frailty in Older Adults | Lifetime | 988 | AU 59 | 94.28 |
| Potassium and Related Disorders | Lifetime | 686 | AU 22 | 88.78 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 634 | AU 13 | 72.57 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 4 | AU 1 | 99.17 |
| COVID-19 Clinical Research Studies | 2021-2025 | 126 | AU 5 | 99.29 |
| COVID-19 and healthcare impacts | 2021-2025 | 50 | AU 2 | 98.45 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 102 | AU 3 | 98.11 |
| Long-Term Effects of COVID-19 | 2021-2025 | 381 | AU 3 | 96.34 |
| Nitric Oxide and Endothelin Effects | 2021-2025 | 20 | AU 2 | 94.87 |
| Chronic Obstructive Pulmonary Disease (COPD) Research | 2021-2025 | 240 | AU 13 | 96.77 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 145 | AU 3 | 96.46 |
| Hematological disorders and diagnostics | 2021-2025 | 40 | AU 2 | 90.58 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 336 | AU 5 | 95.29 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 191 | AU 5 | 94.04 |
| Inflammasome and immune disorders | 2021-2025 | 433 | AU 9 | 88.87 |
| Respiratory Support and Mechanisms | 2021-2025 | 951 | AU 38 | 90.83 |
| Frailty in Older Adults | 2021-2025 | 787 | AU 42 | 89.32 |
| Chronic Disease Management Strategies | 2021-2025 | 635 | AU 37 | 87.41 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 770 | AU 9 | 88.48 |
| Machine Learning in Healthcare | 2021-2025 | 378 | AU 13 | 86.17 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 944 | AU 25 | 87.54 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 339 | AU 12 | 79.87 |
| Angiogenesis and VEGF in Cancer | 2021-2025 | 265 | AU 5 | 76.90 |
| Adenosine and Purinergic Signaling | 2021-2025 | 403 | AU 11 | 75.59 |
| Folate and B Vitamins Research | 2021-2025 | 666 | AU 12 | 73.14 |
| Cell Adhesion Molecules Research | 2021-2025 | 729 | AU 18 | 72.12 |
| Lymphatic System and Diseases | 2021-2025 | 422 | AU 23 | 75.54 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 520 | AU 26 | 71.40 |
| Vitamin C and Antioxidants Research | 2021-2025 | 437 | AU 23 | 68.87 |
| Paraoxonase enzyme and polymorphisms | 2021-2025 | 59 | AU 1 | 68.23 |